![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Spectrum Launches Trial of SPI-153 in Hormone-Dependent Prostate Cancer
Spectrum Launches Trial of SPI-153 in Hormone-Dependent Prostate Cancer
Spectrum Pharmaceuticals has announced the launch of a Phase II trial to evaluate the safety and efficacy of SPI-153 as a treatment for patients with hormone-dependent prostate cancer.
The multicenter Phase II trial is designed to evaluate the effects of SPI-153 on hormonal levels, in particular testosterone, as well as objective antitumor effects. The trial will be conducted in Europe with the collaboration of AEterna Zentaris
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct